Drug
ALD403
ALD403 is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
50%(2 trials)
Phase Distribution
Ph phase_2
1
25%
Ph phase_3
1
25%
Ph phase_1
2
50%
Phase Distribution
2
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
4 of 4 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(4)
Detailed Status
Completed4
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 12 (50.0%)
Phase 21 (25.0%)
Phase 31 (25.0%)
Trials by Status
completed4100%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_3
A Multicenter Assessment of ALD403 in Frequent Episodic Migraine
NCT02559895
completedphase_2
A Multicenter Assessment of ALD403 in Chronic Migraine
NCT02275117
completedphase_1
Safety, Efficacy and Pharmacokinetics of ALD403
NCT01772524
completedphase_1
Safety Tolerability and Pharmacokinetics of ALD403
NCT01579383
Clinical Trials (4)
Showing 4 of 4 trials
NCT02559895Phase 3
A Multicenter Assessment of ALD403 in Frequent Episodic Migraine
NCT02275117Phase 2
A Multicenter Assessment of ALD403 in Chronic Migraine
NCT01772524Phase 1
Safety, Efficacy and Pharmacokinetics of ALD403
NCT01579383Phase 1
Safety Tolerability and Pharmacokinetics of ALD403
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4